Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E1 + G1
- Development stage
- Unknown
- Lead developer
- OPKO Health
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
E1 + G1 is an investigational combination therapy consisting of a recombinant human epidermal growth factor (E1) and a gastrin analogue (G1). Originally developed by Transition Therapeutics and later acquired by OPKO Health, this regenerative biologic therapy is designed to treat Type 1 diabetes by restoring pancreatic beta-cell mass. The treatment aims to stimulate both the neogenesis of new islet cells from ductal precursor cells and the replication of existing beta cells. By acting as a dual agonist for the Epidermal Growth Factor Receptor (EGFR) and the Cholecystokinin B receptor (CCKBR), the combination therapy seeks to re-establish endogenous insulin production and reverse hyperglycemia. Clinical development has primarily focused on Phase 1 and Phase 2 trials to evaluate safety and efficacy, though concerns regarding the long-term use of EGF due to its potential role in oncogenesis have been noted.
- Other names
- gastrin + epidermal growth factorgastrin + EGFE1/G1EGF + Gastrin
02
Targets
EGFR (Epidermal growth factor receptor)CCK2R (Cholecystokinin 2 Receptor)
Beyond the preview
Go deeper on E1 + G1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E1 + G1.